Atea Pharmaceuticals, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $710.1M | $764.4M |
| FY2022 | — | $640.6M | $188.5M |
| FY2023 | — | $555.2M | $143.8M |
| FY2024 | — | $438.9M | $64.7M |
| FY2025 | — | $275.4M | $95.7M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $710.1M | $764.4M |
| FY2022 | — | $640.6M | $188.5M |
| FY2023 | — | $555.2M | $143.8M |
| FY2024 | — | $438.9M | $64.7M |
| FY2025 | — | $275.4M | $95.7M |